Related to Exelixis Scores First FDA Approval for Thyroid Cancer Drug

• EMA Road Map Aims to Stimulate Drug Development for Unmet Medical Needs and Rare and Neglected Diseases
  
• FDA Clears Expanded Access Program for Edison’s Mitochondrial Diseases Candidate
  
• Amgen’s Xgeva Approved by EC for Treating SREs in Adults with Solid Tumor-Related Bone Metastases
  
• EC Sanction of DuoCort’s Plenadren Triggers ViroPharma’s $33M Acquisition of Swedish Firm
  
• Pfizer’s Vyndaqel Gets EC Approval for Transthyretin Familial Amyloid Polyneuropathy Therapy
  
• Nearly Two-to-One Majority Sees FDA or EMA Approval of Gene Therapy by 2013
  
• Even Split on OS vs. PFS As Primary Endpoint for Cancer Drug Approvals
  
• Protalix, Pfizer Report FDA Approval of Plant-Derived Gaucher Disease ERT Elelyso
  
• Exelixis Broadens Cabozantinib Program Through CRADA with NCI-CTEP
  
• Phase III Study Shows Exelixis’ Cabozantinib Nearly Triples PFS in Metastatic Medullary Thyroid Cancer
  
• FDA Clears Beckman Coulter’s phi Blood Test for Prostate Cancer
  
• FDA Approves Qiagen’s KRAS Companion Diagnostic And New Use for Erbitux
  
• FDA Clears First New G-CSF Neutropenia Therapy in 10 Years
  
• Novel Treatment for Most Common Type of Lung Cancer
  
• FDA Approves Novartis' Flucelvax
  
• FDA Blocks Novo, Boosts Celgene
  
• Roche's Genentech Wins FDA OK for Breast Cancer Drug
  
• Bayer Prostate Cancer Drug Gains FDA Approval
  
• Exelixis, NCI to Develop Cabozantinib Against Multiple Cancers
  
• Genzyme Gets FDA, EMA Approvals for Production Plant in Waterford, Ireland